Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill
cancer cells. Combining chemotherapy with interleukin-2 and GM-CSF may be a more effective
treatment for kidney cancer.
PURPOSE: Phase II trial to study the effectiveness of low-dose interleukin-2, vinblastine,
and GM-CSF in treating patients with metastatic kidney cancer.